Anzeige
Mehr »
Login
Dienstag, 18.03.2025 Börsentäglich über 12.000 News von 691 internationalen Medien
Spektakuläre News bei dieser Aktie - ist das ist die Chance des Jahres?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C4Y0 | ISIN: KYG0028A1085 | Ticker-Symbol: 8ZD
Frankfurt
18.03.25
09:15 Uhr
0,895 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ABBISKO CAYMAN LTD Chart 1 Jahr
5-Tage-Chart
ABBISKO CAYMAN LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,3940,47407:00

Aktuelle News zur ABBISKO CAYMAN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ...-
MiABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS1
ABBISKO CAYMAN Aktie jetzt für 0€ handeln
06.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR, FROM THE CHINA CDE2
04.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ...-
04.03.ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS1
03.03.ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE-
03.03.ABBISKO-B (02256): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024; (2) CHANGE IN USE OF NET PROCEEDS; (3) INSIDE INFORMATION; AND ...-
28.02.ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS1
28.02.ABBISKO-B (02256): (1) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR; (2) CHANGE IN COMPOSITION OF AUDIT COMMITTEE, REMUNERATION COMMITTEE AND NOMINATION ...1
17.02.ABBISKO-B (02256): DATE OF BOARD MEETING1
20.01.BRIEF: Abbisko moves into the black in 20241
20.01.ABBISKO-B (02256): POSITIVE PROFIT ALERT1
20.12.24ABBISKO-B (02256): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS2
20.12.24ABBISKO-B (02256): RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MATTERS RELATING TO RULE 13.92 OF THE LISTING RULES1
16.12.24ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - CDE APPROVAL TO INITIATE A REGISTRATIONAL CLINICAL STUDY OF IRPAGRATINIB (ABSK011) IN PATIENTS WITH HCC1
11.12.24ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL STUDY OF ABSK043, AN ORAL PD-L1 SMALL-MOLECULE INHIBITOR, IN COMBINATION ...2
09.12.242024 ASH Oral Presentation: Abbisko presents promising preliminary phase 2 study results of pimicotinib in the treatment of Chronic Graft-versus-Host Disease (cGvHD) at the 66th ASH Annual Meeting101SHANGHAI, Dec. 8, 2024 /PRNewswire/ -- December 8, 2024, Abbisko Therapeutics (HKEX: 02256) announced the presentation of preliminary Phase 2 study results for pimicotinib (ABSK021) in patients...
► Artikel lesen
06.12.24ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ESMO ASIA 2024: ORAL PRESENTATION BY ABBISKO THERAPEUTICS ON UPDATED RESULTS FROM A PHASE I STUDY OF ABSK043, ...1
03.12.24ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - U.S. FDA IND CLEARANCE FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR1
22.11.24ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FIRST-PATIENT DOSED IN GASTRIC CANCER IN PHASE II CLINICAL STUDY EVALUATING ABSK043, AN ORAL PD-L1 INHIBITOR, ...2
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1